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 26 
Abstract 27 
Lysophosphatidic acid (LPA) is a bioactive phospholipid that induces diverse biological 28 
responses. Recently, we found that LPA ameliorates NSAIDs-induced gastric ulcer in mice. Here, 29 
we quantified LPA in 21 medicinal herbs used for treatment of gastrointestinal (GI) disorders. 30 
We found that half of them contained LPA at relatively high levels (40–240 μg/g) compared to 31 
soybean seed powder (4.6 μg/g), which we previously identified as an LPA-rich food. The LPA 32 
in peony (Paeonia lactiflora) root powder is highly concentrated in the lipid fraction that 33 
ameliorates indomethacin-induced gastric ulcer in mice. Synthetic 18:1 LPA, peony root LPA 34 
and peony root lipid enhanced prostaglandin E2 production in a gastric cancer cell line, MKN74 35 
cells that express LPA2 abundantly. These materials also prevented indomethacin-induced cell 36 
death and stimulated the proliferation of MKN74 cells. We found that LPA was present in 37 
stomach fluids at 2.4 µM, which is an effective LPA concentration for inducing a cellular 38 
response in vitro. These results indicated that LPA is one of the active components of medicinal 39 
herbs for the treatment of GI disorder and that orally administered LPA-rich herbs may augment 40 
the protective actions of endogenous LPA on gastric mucosa.   41 
Keywords: Lysophosphatidic acid; Medicinal herbs; Indomethacin; Prostaglandin E2; Cell 42 
death; Cell proliferation 43 
Abbreviations: GI, gastrointestinal; LPA, lysophosphatidic acid; PA, phosphatidic acid; TLC, 44 
thin-layer chromatography; PL, phospholipid; MALDI-TOF MS, matrix-assisted laser desorption 45 
ionization time-of-flight mass spectrometry; LC/MS/MS, liquid chromatography-tandem mass 46 
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spectrometry; CMC, carboxymethylcellulose; PLA2, phospholipase A2; PGE2, prostaglandin E2; 47 
NSAIDs, non-steroidal anti-inflammatory drugs; COX, cyclooxygenase.  48 
1. Introduction 49 
   Lysophosphatidic acid (LPA) is a bioactive phospholipid that induces diverse cellular 50 
responses including proliferation, protection of cells from apoptosis, and migration of cells [1]. 51 
These cellular responses are mediated through six LPA-specific G-protein coupled receptors, 52 
LPA1–6 [2]. Recent studies have revealed important actions of LPA in the mammalian 53 
gastrointestinal (GI) tract [3, 4]. These include inhibition of diarrhea, regulation of intestinal 54 
electrolyte transport, protection of intestinal cells from apoptosis, and wound healing [5-9].    55 
   Peptic ulcer is a major GI disorder that occurs due to an imbalance in mucosal offensive 56 
(gastric acid secretion) and defensive (gastric mucosal integrity) factors [10, 11]. Infection with 57 
Helicobacter pylori, smoking, drinking alcohol, and chronic ingestion of drugs are major causes 58 
of peptic ulcer. Recently, the number of patients with non-steroidal anti-inflammatory drug 59 
(NSAID)-induced gastric ulcer is increasing due to increased use of NSAIDs for pain treatment 60 
and prevention of thrombosis [12]. NSAIDs cause gastric ulcer by inhibition of cyclooxygenase 61 
(COX)-1 and COX-2, which produce a predominant mucosal defense factor, prostaglandin E2 62 
(PGE2) [13]. Our recent study showed that orally administered synthetic LPA ameliorates 63 
aspirin- and indomethacin-induced gastric ulcer in mice [14, 15]. We also showed that LPA up-64 
regulates COX-2 and enhances production of PGE2 via activation of LPA2 receptors, which are 65 
located on the apical side of gastric mucosal cells [16]. However, further uncharacterized 66 
mechanisms other than COX-2 induction are considered to function in the protective action of 67 
LPA, because LPA protects the gastric mucosa from the acute toxicity of NSAIDs.  68 
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   Medicinal herbs have been traditionally used for the treatment of many diseases, including 69 
gastric ulcer [17]. Considering that some medicinal herbs and vegetables contain LPA 70 
abundantly [18, 19], it is rational to postulate the existence of anti-ulcer medicinal herbs that 71 
contains LPA as an active component. To examine this possibility, we determined the LPA 72 
content of 21 herbs that are traditionally used for the treatment of GI disorders. We also aimed to 73 
examine the effects of LPA and herbal lipids on NSAID-induced gastric ulcer. The results 74 
showed that peony root lipid, which contain highly concentrated LPA, had an ameliorative effect 75 
on NSAID-induced gastric ulcer and enhanced PGE2 production in gastric cells. We also showed 76 
evidence that LPA/LPA2 signaling protects against acute cytotoxicity of NSAIDs in cultured 77 
gastric cells.   78 
2. Materials and Methods 79 
2.1 Materials 80 
   Herbs used for the treatment of various digestive disorders were selected based on the 81 
descriptions in the oldest Chinese traditional herbal medicine book, the Shennong Ben Cao Jing. 82 
Coptis rhizome (Coptis japonica), moutan cortex (Paeonia suffruticosa), atractylodes rhizome 83 
(Atractylodes japonica), atractylodes lancea rhizome (Atractylodes lancea), amomum seed 84 
(Amomum xanthioides), peony root (Paeonia lactiflora), poria sclerotium (Poria cocos), and 85 
phellodendron bark (Phellodendron amurense) were obtained from Yoshimi Seiyaku Co. Ltd. 86 
(Osaka, Japan). Licorice root (Glycyrrhiza glabra), platycodon root (Platycodon grandiflorum), 87 
bupleurum root (Bupleurum falcatum), zedoary rhizome (Curcuma zedoaria), fennel fruit 88 
(Foeniculum vulgare), dried ginger rhizome (Zingiber officinale), and stripped, steamed, and 89 
dried ginger rhizome (Zingiber officinale) were purchased from Nakaya Hikojuro Co. Ltd. 90 
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(Ishikawa, Japan). Sophora root (Sophora flavescens) and schisandra fruit (Schisandra chinensis) 91 
were obtained from Kojima Kampo Co. Ltd. (Osaka, Japan). Pinellia tuber (Pinellia ternata), 92 
cimicifuga rhizome (Cimicifuga simplex), panax rhizome (Panax japonicus), and corydalis tuber 93 
(Corydalis turtschaninovii) were purchased from a local drug store. 94 
2.2 Reagents 95 
   One-oleoyl-2-hydroxy-sn-glycero-3-phosphate (18:1 LPA), 1-heptadecanoyl-2-hydroxy-sn-96 
glycero-3-phosphate (17:0 LPA), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (16:0 97 
LPC), and arachidonic acid were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 98 
Peony root LPA was freshly prepared from peony root powder as described below. Pertussis 99 
toxin (PTX) and calcium ionophore A23187 were purchased from Sigma-Aldrich (St. Louis, MO, 100 
USA). Phos-tag was obtained from Wako Pure Chemical Industries (Osaka, Japan). 101 
Carboxymethylcellulose (CMC), aspirin, and indomethacin were obtained from Kanto Chemical 102 
Co. (Tokyo, Japan), Wako Pure Chemical Industries (Osaka, Japan), and Nacalai Tesque Inc. 103 
(Kyoto, Japan), respectively. A prostaglandin E2 EIA kit was obtained from Cayman Chemical 104 
Co. (Ann Arbor, MI). A lactate dehydrogenase (LDH) assay kit was obtained from Dojindo 105 
Laboratories Co. Ltd. (Kumamoto, Japan). A bromo-2-deoxy-uridine (BrdU) cell proliferation 106 
ELISA kit was purchased from Roche (Mannheim, Germany).  107 
2.3 Animals 108 
   Five-week-old male ICR mice (35g body weight) were obtained from Charles River 109 
Laboratories Japan, Inc. (Kanagawa, Japan). The animals were adapted to an animal room 110 
maintained at 24 ± 2 °C and housed in a 12 h light/dark cycle. The care and handling of mice 111 
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were in accordance with the National Institute of Health guidelines. All experimental procedures 112 
were approved by the Tokushima University Animal Care and Use Committee. 113 
2.4 Extraction of lipid and isolation of LPA from herbs 114 
   Lipids were extracted from the medicinal herbs by the Bligh and Dyer method [20] with 115 
acidification of the water/methanol phase, as described previously [19]. In brief, 1 g of herb 116 
powder was mixed with 15.2 ml of a solvent consisting of chloroform/methanol/water in the 117 
ratio of 1:2:0.8 (v/v/v) and centrifuged to collect the supernatant. The pellet was added to the 118 
same amount of the mixed solvent consisting of chloroform/methanol/water and centrifuged. The 119 
combined supernatant fraction was mixed with an appropriate volume of chloroform and water 120 
to make solvent system consisting of chloroform/methanol/water in the ratio of 1:1:0.9 (v/v/v). 121 
The resulting two-layer solution was mixed with 0.15 ml of 5 N HCl and centrifuged. Lipids 122 
were obtained from the lower phase (chloroform phase). The LPA in the lipid extract was 123 
isolated by TLC. The solvent system of the chromatography was chloroform/methanol/28% 124 
aqueous ammonia (60:35:8, v/v/v). After development, the plate was dried for a few minutes 125 
with blowing air and sprayed with primulin for visualization under UV light. LPA was identified, 126 
extracted from the silica gel by the Bligh and Dyer method [20], and quantified by the 127 
colorimetric method based on phospho-molybdenum-malachite green formation [21]. The weight 128 
of phospholipids (μg/g) was determined from a weight of lipid phosphorus (µg inorganic 129 
phosphorus/g) in a way recommended by American Oil Chemists’ Society [22]. 130 
 2.5 Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-131 
TOF MS) 132 
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   Molecular species of LPA in herbs were determined by MALDI-TOF MS as described 133 
previously [15]. An aliquot of LPA was dissolved in 100 µl of methanol containing 0.1% 134 
aqueous ammonia. This solution (10 µl) was mixed with 5 µl 0.1 mM 68Zn Phos-tag solution. A 135 
small portion (0.5 µl) of this mixture was spotted on a sample plate. Immediately, 0.5 µl of 2, 4, 136 
6-trihydroxyacetophenone (THAP) solution (10 mg/ml in acetonitrile) was layered onto the 137 
mixture as a matrix solution. The sample plate was dried for a few minutes, and the 138 
matrix/analyte co-crystal that formed was subjected to MALDI-TOF MS. MALDI-TOF mass 139 
spectra were acquired using a Bruker Microflex mass spectrometer (Bruker Daltonics, Bremen, 140 
Germany) in positive ion detection mode. The wavelength of the nitrogen-emitting laser and the 141 
accelerating voltage were 337 nm and 20 kV, respectively. To enhance the reproducibility, 300 142 
laser shots were averaged for each mass spectrum.  143 
2.6 NSAIDs-induced gastric ulcer 144 
   Mouse models of aspirin- and indomethacin-induced gastric ulcer were developed as described 145 
previously [14, 15]. In brief, aspirin (300 mg/kg body weight), indomethacin (22.9 mg/kg body 146 
weight), or peony root lipid was suspended in 3% (w/v) CMC and sonicated for 1 min. Peony 147 
root powder was suspended in water. Fasted mice were intragastrically administered peony root 148 
lipid or powder suspension in a volume of 0.2 ml. After 0.5 h, 0.2 ml of the aspirin or 149 
indomethacin suspension was administered intragastrically. The mice were anesthetized with 150 
diethyl ether and sacrificed 3 or 5 h after the aspirin or indomethacin administration, respectively. 151 
The isolated stomach was ligated at both ends, filled with 1.5 ml of 2% formalin, and immersed 152 
in 2% formalin for 15 min. Then, the stomach was cut along the greater curvature, and the 153 
lengths of lesions on the stomach wall were measured using a millimeter scale with a magnifying 154 
glass. The total length of lesions was used as a lesion index. 155 
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2.7 Cell culture and reverse transcription-PCR (RT-PCR) 156 
    MKN74 cells, a human gastric cancer cell line, were obtained from the RIKEN Cell Bank 157 
(Tsukuba, Japan). The MKN74 cells were grown in RPMI-1640 medium containing 10% fetal 158 
bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin in a humidified 159 
atmosphere of 5% CO2 and 95% air at 37 ºC. Total RNA from MKN74 cells was prepared by 160 
using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's 161 
instructions. The first-strand complementary DNA (cDNA) was synthesized from the purified 162 
total cellular RNA with random hexamer primers using the SuperScript™ III synthesis system 163 
for RT-PCR kit (Invitrogen, Carlsbad, CA). The cDNA was then subjected to PCR amplification 164 
with primer sets and condition as described in supplementary Table 1. The PCR products were 165 
examined by electrophoresis on 2% agarose gel, stained with Gelred (Biotium, Hayward, CA) 166 
and visualized with UV light. Images of the fluorescent band on the gel were captured by a Fuji 167 
LAS-4000 imaging system (FujiFilm, Tokyo, Japan), and the digitized image data were analyzed 168 
by NIH image.  169 
2.8 PGE2 production assay 170 
  PGE2 production in MKN74 cells was performed as described previously [16].  In brief, 171 
MKN74 cells were seeded in 35-mm dishes and added 10 µM arachidonic acid (AA) for AA-172 
enrichment in the cells. After 24 h, the medium was changed to serum-free medium, and further 173 
incubated for 24 h. Then, the cells were treated with 10 µM acetylsalicylic acid for 30 min to 174 
minimize the effect of the preexisting COX activity. After replacement of the medium, cells were 175 
incubated with 18:1 LPA, peony root lipid extract or purified peony root LPA in the presence or 176 
absence of pertussis toxin (PTX). After 5 h, the cells were stimulated with 1 µM A23187 for 10 177 
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min. The supernatant were collected and PGE2 was evaluated by EIA kit according to the 178 
manufacturer’s instructions.  179 
2.9 Indomethacin-induced cell damage of MKN74 cells 180 
MKN74 cells were seeded at a density of 1x105 in 35-mm polystyrene dishes and serum starved 181 
for 24 h. LPA dissolved in 0.3% BSA in PBS were added 2 h before addition of indomethacin 182 
solution. The final concentration of indomethacin was fixed at 0.8 mM. After 30 h, the cells were 183 
gently washed with PBS and stained with propidium iodide (PI) for 30 min. The extent of cell 184 
death was determined by observation with a fluorescent microscope Axiovert 200 M (Zeiss, 185 
Oberkochen, Germany). For the LDH assay, MKN74 cells were treated in the same manner as 186 
described above. At the end of incubation, 100 μl of the culture medium supernatant was added 187 
per well of a 96-well microplate. The LDH activity was measured according to the instructions 188 
of the LDH assay kit. The activity was expressed as % of maximum release of LDH that can be 189 
obtained in a sample of the lysis buffer-treated cells. The extent of cell death was also 190 
determined by flow cytometric analysis. The PI-stained cells were subjected to a flow cytometer 191 
(Becton Dickinson) that was operated using Cell Quest software, and at least 10,000 cells were 192 
analyzed for each sample.  193 
2.10 Cell proliferation assay  194 
   MKN74 cells seeded in 35-mm polystyrene dishes were serum-starved for 24 h. Then they 195 
were cultured with or without synthetic or peony root-derived LPA in the presence or absence of 196 
PTX. After 24 h, cells were harvested by trypsinization, mixed with trypan blue dye, and the 197 
number of living cells was counted using a hemocytometer. The proliferation of MKN74 cells 198 
was also confirmed by a BrdU cell proliferation assay. In brief, 2x103 cells were seeded in 96-199 
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well microplates in 100 μl/well culture medium and kept in serum-starved condition for 48 h. 200 
The synthetic or peony root-derived LPA was added to the cells and further incubated for 24 h. 201 
BrdU was added to the cell culture 4 h before termination of incubation. The incorporated BrdU 202 
was determined as described by the manufacturer’s protocol. 203 
2.11 Determination of LPA in a mouse stomach fluid  204 
   Stomachs of overnight-fasted mice were isolated and gently washed with PBS. The stomach 205 
was cut along the greater curvature. The stomach inner surface was carefully washed with a 206 
small amount of PBS. After addition of 17:0 LPA (0.5 nmol) as an internal standard, lipids were 207 
extracted from the stomach washing solution by using an acidified Bligh and Dyer method as 208 
described above. Extracted lipids were dissolved in 0.8 ml of methanol and filtered through 0.2 209 
µm  nylon filter. After filtration, methanol was evaporated and reconstituted in 0.1 ml of 210 
methanol/water mixture (95:5, v/v) containing 5 mM ammonium formate for LC/MS/MS. 211 
LC/MS/MS was performed as described previously [23] using a quadrupole-linear iontrap hybrid 212 
mass spectrometry system, 4000 Q TRAP™ (Applied Biosystems/MDS Sciex, Concord, Ontario, 213 
Canada) with an Agilent 1100 liquid chromatography system (Agilent Technologies, 214 
Wilmington, DE, USA). In the negative ion mode of operation with multiple reactions 215 
monitoring, Q1 was set to the deprotonated molecular ion of each class of LPA as the precursor 216 
ion. The fragment ions, [deprotonated cyclic glycerophosphate]− at m/z 153 were selected for Q3. 217 
The ratios of the negative ion peak areas of the endogenous LPA to that of the corresponding 218 
internal standard were calculated.  219 
 2.12 Statistical analysis 220 
    Statistical analyses of the difference between two means were performed by Student’s t-test. 221 
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 222 
3. Results 223 
3.1 Abundance of LPA in medicinal herbs 224 
 Our previous study [19] revealed that LPA is abundant in cruciferous plants, such as cabbage 225 
leaves and radish roots (9.2 and 2.3 μg/g wet weight, respectively). Soybean seed powder was 226 
also found to be rich in LPA (4.6 μg/g). In this study, we determined LPA content in 21 dried 227 
medicinal herbs used for the treatment of GI disorders (Fig. 1A). Compared to LPA-rich foods, 228 
about half of the medicinal herbs contained LPA at high levels (40–240 μg/g). Among them, 229 
peony root powder (240 μg/g) contained the highest level of LPA. It was 52 times that of 230 
soybean seed powder. We previously revealed that phosphatidic acid (PA), a diacyl derivative of 231 
LPA, serves as a source of LPA in the digestive tract [14]. The amounts of PA in these medicinal 232 
herbs were comparable (Fig. 1B) to those in cabbage and soybean, which were characterized as 233 
PA-rich foods previously [24]. Surprisingly, the percentage of LPA in total phospholipids (PLs) 234 
in peony root was 11%, which is 30 and 400 times of those in cabbage leaves and soybean seed 235 
powder, respectively (Table 1). These results indicated that peony root powder contains abundant 236 
LPA with a high concentration in its lipid fraction. This is evident from the relative intensity of 237 
TLC bands of its lipid extract (Supplementary Fig. 1).   238 
   MALDI-TOF MS of PA and LPA in medicinal herbs showed that the predominant PA species 239 
were 16:0/18:2 and 18:2/18:2 (or 18:1/18:3) PA (Supplementary Table 2) and the predominant 240 
LPA species were 16:0, 18:2 LPA (Supplementary Table 3). This is also the case in peony root 241 
as shown in Fig. 2A, B.  242 
3.2 Anti-ulcer effect of peony root lipid and powder 243 
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   As shown previously, orally administered aspirin (300 mg/kg body weight) produces 15–20 244 
mucosal lesions in the gastric corpus of mice [14]. The lesions were linear and extended from the 245 
fundic area to the pyloric area as erosion. Similar morphological lesions were observed in the 246 
experiments with indomethacin (22.9 mg/kg body weight) (Fig. 3A). We used the total length of 247 
lesions as the lesion index.  248 
   Orally administered peony root lipid reduced indomethacin-induced lesion formation in a dose-249 
dependent fashion (Fig. 3A, B). The maximum reduction was observed when mice were 250 
administered 1 mM of peony root lipid (Fig. 3A, B), which corresponds 4.4 mg PLs/kg (animal 251 
body weight). We confirmed that synthetic LPA at 1 mM has protective effect against 252 
indomethacin-induced lesion formation (Fig. 3B). We also examined the gastro protective effect 253 
of peony root powder on an aspirin-induced acute gastric ulcer mouse model. The peony root 254 
powder at 2 g/kg body weight effectively reduced gastric mucosal lesion formation (Fig. 3C). 255 
This dose of the powder corresponds to the administration of 1 mM peony root lipid.  256 
3.3 Enhancement of PGE2 production by LPA-rich herbal lipids in gastric cells    257 
   According to the Human Protein Atlas database (http://www.proteinatlas.org/), LPA2, LPA5, 258 
and LPA6 are expressed abundantly in human stomach epithelia. On the other hand, expression 259 
levels of LPA1, LPA3, and LPA4 are very low. Firstly, we examined LPAR1–6 mRNA expression 260 
in human gastric cancer cell line, MKN74 cell. Results showed that order of abundance of LPAR 261 
mRNA was LPA2=LPA5>LPA6. Levels of mRNA of LPA1, LPA3, and LPA4 were under 262 
detectable (Fig. 4A). The relative abundance of mRNA of LPARs in MKN74 cells is good 263 
agreement with the expression profile of LPARs in human stomach tissue. We used this cell line 264 
as a representative mucosal cell model of the human stomach. We confirmed that synthetic 18:1 265 
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LPA can enhance PGE2 production in MKN74 cells (Fig. 4B). This is consistent with our 266 
previous observation that LPA enhances PGE2 production via up-regulation of COX-2 [16].  267 
This effect was also observed with LPA prepared from peony root. Peony root lipid, which has 268 
concentrated LPA, enhanced PGE2 production at high efficacy. Enhancements of PGE2 269 
production induced by LPA and peony root lipid were completely abolished by PTX (Fig. 4C), 270 
suggesting the involvement of Gi-coupled receptor in their actions. It should be mentioned that 271 
high concentration of the peony root lipid (10 µM) did not induce PGE2 production (Fig. 4B). 272 
This is due to cytotoxicity of the lipid extract which contain various components other than LPA.  273 
In fact, we observed that most of the cells were floating at the end of the incubation with peony 274 
root lipid at 10 µM.   275 
3.4 LPA protects indomethacin-induced cell injury of MKN74 cells  276 
  Effect of LPA on indomethacin-induced cell injury was examined in MKN74 cells. As shown 277 
in Fig 5A, non-treated MKN74 cells were tightly attached each other. We found that treatment of 278 
the cells with 0.8 mM indomethacin results in loss of attachment and rounding of their cell shape 279 
(Fig. 5A), a typical morphological change in apoptotic cells [25, 26]. When the cells were treated 280 
with 0.8 mM indomethacin plus 10 µM LPA, the indomethacin-induced morphological change 281 
was not observed. In fact, LPA caused cell spreading with an extended edge, indicating the 282 
disappearance of apoptotic symptoms (Fig. 5A). The protective action of LPA on indomethacin-283 
induced cellular damage was quantified by directly counting PI-positive cells (dead cells). We 284 
found that LPA reduced the number of PI-positive cells in a dose-dependent fashion (Fig. 5B). 285 
LPA from peony root also significantly reduced cell death at 10 µM (Fig. 5B). The protective 286 
action of LPA against indomethacin-induced cellular damage was also confirmed by LDH 287 
leakage (Fig. 5C). To determine the involvement of G-protein-coupled receptors in these 288 
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observations, the effect of pretreatment of PTX, a specific inhibitor of Gi-protein, was examined. 289 
Flow cytometric analysis was applied for this experiment to quantify the population of dead cells 290 
in the total cells. Results showed that the effect of LPA against indomethacin-induced cell death 291 
was completely abolished by pre-treatment of PTX, indicating the involvement of Gi-coupled 292 
receptors in the LPA action (Fig. 5D). This is also confirmed by the morphological change of the 293 
cells (data not shown). We found that LPC did not show a protective effect on indomethacin-294 
induced cell death (Fig. 5D).  295 
3.5 LPA stimulated proliferation of MKN74 cells  296 
   Treatment of MKN74 cells with LPA induced proliferation in a dose-dependent manner (Fig. 297 
6A). LPA-induced cell proliferation was also confirmed by measuring incorporation of the 298 
thymidine analog BrdU into the cells (Fig. 6B). Peony root LPA also stimulated the proliferation 299 
of MKN74 cells (Fig. 6A, B). LPA-induced cell proliferation was partially and significantly 300 
inhibited by PTX (Fig. 6C). Again, LPC had no proliferative effect. 301 
3.6 LPA concentration in a mouse stomach fluid 302 
   In order to better understand the role of LPA in the physiology of the stomach, it is necessary 303 
to know the concentration and molecular species of LPA in stomach fluid. The volume of 304 
stomach fluid was assumed to be 0.08 ml. This is based on the fact that the area of the mucus 305 
layer is 400 mm2 and the thickness of mucus gel layer is 0.2 mm [27]. We found that the total 306 
LPA concentration in the stomach fluid was 2.4 μM (Fig. 7). The major species of LPA in the 307 
stomach fluid were found to be 16:0, 18:0, 18:1, and 18:2 LPAs (Fig. 7). The concentration of 308 
these LPA species was found to be 0.3–0.7 µM. Other LPA species, such as 16:1, 18:3, 18:4, 309 
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20:0, 20:1, 20:2, 20:4, 22:0, 22:4, and 22:6, were present in low (0.01–0.1 μM) level 310 
(Supplementary Fig. 2). 311 
4. Discussion 312 
   Research in medicinal herbs has identified many active components that exert anti-ulcer effects 313 
with diverse mechanisms of action. These include compounds belonging to flavonoids, alkaloids, 314 
tannins, and saponins [28, 29]. Dietary phospholipids, such as soy-derived PC, are also shown as 315 
reducing agents for NSAIDs-induced gastric ulcer [30]. In this study, we found that LPA in 316 
medicinal herbs is a potential component for prevention of gastric mucosal injury. This notion is 317 
based on several observations. Firstly, synthetic LPA and herbal LPA showed ameliorative 318 
activity against cytotoxic effect of indomethacin. Secondly, LPAs and LPA-rich lipid enhanced 319 
PGE2 production, an important cytoprotective factor in GI mucosa. Thirdly, peony root lipid, an 320 
LPA-rich herbal lipid identified here, significantly ameliorated indomethacin-induced gastric 321 
lesions in mice. Lastly, there were many LPA-rich herbs in Chinese traditional medicines used 322 
for the treatment of GI disorders. We discuss on mechanisms of these effects in detail.  323 
   A well-known mechanism of NSAID-induced gastric mucosal lesions is the inhibition of 324 
COX-1 and COX-2 enzymes and a resulting decrease in gastroprotective PGE2. The importance 325 
of PGE2 in the integrity of stomach mucosa is evident from the fact that common anti-ulcer drugs, 326 
such as rebamipide and geranylgeranylacetone, up-regulate COX-2, leading to the enhancement 327 
of PGE2 production [31, 32]. Consistent with our previous study [16], LPA from medicinal herb 328 
was found to enhance PGE2 production in human gastric cancer cell line, MKN74 cells. We also 329 
showed that peony root lipid, which has concentrated LPA, enhanced PGE2 production with Gi-330 
mediated manner. Surprisingly, the efficacy of PGE2 production of peony root lipid is higher 331 
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than that expected from the LPA content in the lipid extract. At present, we do not know other 332 
components in peony root lipid that enhance PGE2 production along with LPA. Considering that 333 
PGE2-enhancement was completely abolished by PTX, there may be components that increase 334 
LPA action in the lipid. Further study is needed for clarification of this point.    335 
   NSAIDs have been reported to induce apoptosis in gastric mucous cells [25, 26]. The 336 
mechanism of the cytotoxicity is uncoupling of mitochondrial oxidative phosphorylation and 337 
inhibition of the electron transport chain, leading to depletion of intracellular ATP, cellular Ca2+ 338 
toxicity, and generation of reactive oxygen species [13]. It is also reported that NSAIDs 339 
chemically interact with cell membrane phospholipids, disrupt membrane permeability, and form 340 
membrane pores [13]. In this study, we found that pretreatment of MKN74 cells with LPA 341 
prevents indomethacin-induced cell shape change, LDH leakage and cell death. The protective 342 
effect of LPAs against indomethacin-induced cell death was completely abolished by PTX, 343 
indicating the involvement of Gi-coupled receptor.  344 
   It has been reported that LPA stimulates proliferation of diverse types of cells, including 345 
gastric cancer cells [33]. In this study, we found that LPA stimulated proliferation of MKN74 346 
cells. The proliferative effect of LPA was partially but significantly abolished by PTX. The 347 
partial inhibition of PTX in LPA-induced proliferation of MKN74 indicates the involvement of 348 
Gi as well as G12/13 and Gq/11/14 in the LPA response. Our result is consistent with previous 349 
reports showing that LPA stimulates proliferation of NIH3T3 in both PTX- sensitive and -350 
insensitive manners [34].  351 
   We observed membrane budding-like structure in LPA-treated MKN74 cells (Supplementary 352 
Fig. 3). They form almost vesicles, and their size is considerably smaller than those of LPA-353 
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induced membrane blebs reported by Valentine et al. [35]. At present, we do not know the 354 
biological significance of this phenomenon induced by LPA. Miyake et al. reported that MKN28 355 
cells secrete mucin when the plasma membrane of the cells is injured in the presence of calcium 356 
[36]. They also found microvilli on the plasma membrane of MKN28 cells. If the phenomenon 357 
observed here is one of the steps of mucin secretion from gastric cells, the physiological function 358 
of the LPA-induced vesicle secretion is to strengthen the mucus gel layer, a protective barrier of 359 
the stomach wall. 360 
   We found that LPA2 and LPA5 are predominant LPAR in MKN74 cells. This is good 361 
agreement with the expression profile of LPARs in human stomach tissue 362 
[http://www.proteinatlas.org/]. Here, we showed that LPA-induced PGE2 production, anti-363 
apoptosis, and proliferation in MKN74 cells were all Gi-mediated responses. LPA2 has been 364 
known to couple with Gi in many cells [8, 37, 38]. On the other hand, LPA5 seems to be coupled 365 
with Gq rather than Gi in many cells [39, 40]. Considering these facts, it is reasonable to assume 366 
that LPA2 is involved in these observations and that LPA2 expressed on the apical membrane of 367 
gastric mucous cells [16] plays important role in gastric mucosal integrity.   368 
      In this study, for the first time, we determined the LPA concentration in stomach fluid. We 369 
found that LPA concentration in stomach fluid was 2.4 µM. The LPA concentration in stomach 370 
fluid is three times higher than that in saliva (0.9 µM) [41] and similar or relatively higher level 371 
to that in human plasma or serum LPA (0.1–2.4 μM) [42-44]. The presence of LPA in stomach 372 
fluid is reasonable because LPA receptors are expressed in the apical side of gastric mucosal 373 
cells [14, 16]. We found that the level of LPA in the stomach fluid is in a range that induces a 374 
diverse response in gastric cells in vitro (Fig. 4, 5, 6). We also found that the abundant LPA 375 
species in the stomach fluid were 16:0, 18:0, 18:1, and 18:2 LPA. These LPA species are potent 376 
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agonists for LPA receptors [45] and showed potent gastro protective effects in vivo and in vitro 377 
(Fig. 3, 5 ). These results suggested that endogenous LPAs have a possibility to play vital roles in 378 
gastric epithelial cells, and that ingested LPAs contribute to mucosal integrity by augmentation 379 
of LPA in stomach fluid.      380 
5. Conclusion  381 
   The present study revealed the abundant existence of LPA in medicinal herbs that are used for 382 
treatment of GI disorders. An LPA-rich herb, peony root had a significant gastro protective effect 383 
on NSAID-induced gastric ulcer. We also revealed that in addition of PGE2 enhancement, LPA 384 
protects against NSAID-induced acute cell toxicity and stimulates the proliferation of gastric 385 
cells. LPA2 in gastric mucosal cells are considered to be involved in these LPA actions.  386 
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 542 
 Fig. 1. Abundance of LPA in medicinal herbs 543 
Amounts of (A) LPA and (B) PA isolated from herbs were determined by measurement of their 544 
lipid phosphorus. Data represent means ± SD of three independent experiments. Herbs and foods 545 
except for cabbage leaves were dry weight. ND: Not detectable (less than 2 µg/g).  546 
 547 
 27 
 548 
Fig. 2. MALDI TOF mass spectra of PA and LPA isolated from peony root 549 
(A) PA and (B) LPA from peony root were analyzed by MALDI-TOF MS as their Phos-tag 550 
complexes. Chemical structure shown is a complex of a phosphate monoester compound with 551 
Phos-tag.   552 
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 553 
Fig. 3. Anti-ulcer effect of peony root lipid and powder 554 
(A, B) Peony root lipid was suspended in 3% CMC. Aliquots of the suspension (0.2 ml) were 555 
orally administered to mice. After 30 min, 0.2 ml of indomethacin (22.9 mg/kg) in 3% CMC was 556 
intragastrically administered. The total lengths of lesions on the stomach wall were measured at 557 
5 h after injection of indomethacin. (B) Indicated concentrations are based on the amounts of 558 
total phospholipid. For example, “1 mM PL” indicates administration of peony lipid containing 559 
0.2 µmol of phospholipid in 0.2 ml of the suspension. Values in the parenthesis indicate 560 
concentrations of LPA in peony root lipid suspensions. This is deduced from Table1.  The 561 
numbers of mice of each group were 15 for control (0 mM) and 5–15 for others. ***P<0.005 562 
versus control. (C) Mice were intragastrically administered 0.2 ml water or 0.2 ml peony root 563 
powder suspended in water. Peony root powder in a dose of 2 g/kg body weight contains 1 mM 564 
phospholipids. Mice were sacrificed 3 h after aspirin administration (300 mg/kg). The numbers 565 
of mice of each group were 5–10. ***P<0.005 versus control. Synthetic LPA (16:0 LPA) at 1 566 
mM (5.7 µmol/kg body weight) was used as positive control. Error bar represents SD. 567 
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 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
Fig. 4. Enhancement of PGE2 production by LPA and peony root lipid. 581 
(A) mRNA profile of LPARs (LPA1-6) of MKN74 cells. (B) MKN74 cells repleted with 582 
arachidonic acid were preincubated with the indicated concentration of LPA or peony root lipid 583 
for 5 h before stimulation with 1 µM A23187 for 10 min. PGE2 released into the culture media 584 
was measured using an ELISA kit. Indicated values in parenthesis are the concentration of LPA 585 
in the peony root lipid. Each value shown is mean ± SD. (C) MKN74 cells were incubated with 586 
3 µM synthetic LPA (18:1 LPA) or 3 µM peony root lipid in the absence or presence of 100 587 
ng/ml of PTX for 5 h before stimulation with 1 µM A23187 for 10 min. PGE2 released into the 588 
culture media was measured using an ELISA kit. Each value shown is the mean ± SD. *P<0.05, 589 
**P<0.01, ***P<0.005 versus control and ## P<0.01.  590 
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 591 
Fig. 5. LPA protect indomethacin-induced cell injury in MKN74 cells. 592 
(A) Serum-starved MKN74 cells were incubated with 0.8 mM indomethacin with or without 10 593 
μM 18:1 LPA. After 30 h, dead cells are stained with propidium iodide (PI). The image shown is 594 
phase-contrast microscopic photo merged with a fluorescent microscopic photo for indication of 595 
PI-positive cells. (B, C) Serum-starved MKN74 cells were incubated with 0.8 mM indomethacin 596 
in the absence or presence of increasing concentration of LPAs. (B) The percentage of dead cells 597 
 31 
was calculated by counting PI-positive cells in several randomized subfields in each dish from 598 
three different experiments. (C) LDH leakage in the culture media was determined to know the 599 
extent of the cellular damage. (D) MKN74 cells were incubated with 0.8 mM indomethacin in 600 
the absence or presence of 10 μM 18:1 LPA or 16:0 LPC with or without PTX (100 ng/ml). Flow 601 
cytometry was performed 30 h after indomethacin treatment. Values in the flow cytometry chart 602 
indicate the % of dead cells. Data represent means ± SD of three independent experiments. 603 
*P<0.05, **P<0.01, ***P<0.005 versus control and ## P<0.01.  604 
  605 
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 606 
 607 
Fig. 6. LPA stimulated proliferation of MKN74 cells 608 
(A, B) MKN74 cells were serum starved for 24 h, and then, treated with different concentrations 609 
of LPA. After 24 h, the extent of proliferation was determined by direct counting or BrdU 610 
incorporation. (C) The proliferation assay was conducted in the presence or absence of 100 611 
ng/ml of PTX or with 16:0 LPC (10 μM) instead of 18:1 LPA. Data represent means ± SD of 612 
three independent experiments. *P<0.05, **P<0.01 versus control and #P<0.05. 613 
 614 
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 615 
Fig. 7. LPA concentration in a mouse stomach fluid 616 
Stomachs of fasted mice were isolated and cut along the greater curvature. The stomach mucosal 617 
surface was washed with a small amount of PBS. Lipids were extracted from the stomach 618 
washing solution and subjected to LC/MS/MS by using 17:0 LPA as an internal standard. Data 619 
represent means ± SD of three independent experiments.  620 
  621 
 34 
Table 1 622 
LPA is highly concentrated in the lipid fraction of peony root. 623 
                                                           Cabbage         Soybean         Peony root 
                            µg/g ( %) µg/g    (%) µg/g  (%) 
Total 
phospholipid 
2300 ± 160   - 13000 ± 2700   - 2200 ± 140      - 
PA   540 ± 110 (24)     450 ± 20  (3.0)   460 ± 20      (21) 
LPA       9 ± 1 (0.4)        5  ± 2 (0.03)   240 ± 20      (11) 
Value in cabbage is wet weight. Values in soybean and peony root are dry weight. Values in 624 
parentheses are percentage in total phospholipid.   625 
Supplementary Fig. 1  
 
 
Supplementary Fig. 1. Two-dimensional TLC of peony root lipid  
Peony root lipid was separated by two-dimensional TLC. The solvent systems for the first and 
second chromatography were chloroform/methanol/28% ammonia (60:35:8, v/v/v) and 
chloroform/acetone/methanol/acetic acid/water (50:20:10:13:5, v/v/v/v/v), respectively. PA, 
phosphatidic acid; LPA, lysophosphatidic acid; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PI, phosphatidylinositol. Dit, Dittmer-positive spot indicating 
phospholipid. 
 
Supplementary Fig. 2 
 
Supplementary Fig. 2. Determination of LPA molecular species in a mouse stomach fluid 
by LC/MS/MS. 
A stomach of fasted mouse was isolated, and cut along the greater curvature. The stomach inner 
surface was washed with a small amount of PBS. Lipid was extracted from the washing solution, 
and subjected to LC/MS/MS for determination of LPA using 17:0 LPA as an internal standard. 
Supplementary Fig. 3 
 
Supplementary Fig. 3.  LPA-induced structural change in plasma membrane of MKN74 
cells.  
MKN74 cells were treated with 10 μM 16:0 LPA for 3 h and fixed with 3% glutaraldehyde. 
After treatment with 1% osmium, cells were stained with 2% uranyl acetate. Serial section of the 
cells in each 70–80 nm in thickness, were cut with an ultramicrotome and examined with an 
electron microscope. Large protrusions with budded vesicles were observed in plasma membrane 
of the cells.   
  
Supplementary Table 1.  
 Primer sequences and PCR conditions used in this study 
Name                            Sequence  Denaturation    Annealing   Extension 
LPA1  Forward: 5’-GAGGAATCGGGACACCATGAT-3’ 
Reverse: 5’-ACATCCAGCAATAACAAGACCAATC-3’ 
94°C/30 sec 67°C/30 sec 72°C/30 sec 
LPA2 Forward: 5’-CATCATGCTTCCCGAGAACG-3’ 
Reverse: 5’-GGGCTTACCAAGGATACGCAG-3’ 
94°C/30 sec 67°C/30 sec 72°C/30 sec 
LPA3 Forward: 5’-GCTCCCATGAAGCTAATGAAGACA-3’  
Reverse: 5’-AGGCCGTCCAGCAGCAGA-3’ 
94°C/30 sec 67°C/30 sec 72°C/30 sec 
LPA4 Forward: 5’-CAGTGCCTCCCTGTTTGTCTTC-3’ 
Reverse: 5’-GAGAGGGCCAGGTTGGTGAT-3’ 
94°C/30 sec 67°C/30 sec 72°C/30 sec 
LPA5 Forward: 5’-AGCAACACGGAGCACAGGTC-3’  
Reverse: 5’-CCAAAACAAGCAGAGGGAGGT-3’ 
94°C/30 sec 67°C/30 sec 72°C/30 sec 
LPA6 Forward: 5’-CCGCCGTTTTTGTTCAGTC-3’  
Reverse: 5’-GAGATATGTTTTCCATGTGGCTTC-3’ 
94°C/30 sec 67°C/30 sec 72°C/30 sec 
 
 
 
  
Supplementary Table 2. Molecular species composition of PA in medicinal herbs 
                                       *34:3   34:2    34:1   36:5  36:4   36:3   36:2 
Peony root       9     53 −    10    28 − − 
Cimicifuga rhizome −     75 − −    25 − − 
Panax rhizome −     60     16 −    24 − − 
Atractylodes rhizome −     67 − −    33 − − 
Atractylodes lancea rhizome −     66 − −    34 − − 
Phellodendron bark  − − − − − − − 
Ginger rhizome  (steamed) − − − −   100 − − 
Corydalis tuber − − − − − − − 
Licorice root  −      62 − −    38 − − 
Ginger rhizome  (dry)      16      75 − −      9 − − 
Moutan cortex  −      55 − −     45 − − 
Fennel fruit −      32     16 −    16    22    14 
Pinellia tuber  − − − − − − − 
Bupleurum root  −      65 − −     35 − − 
Schisandra fruit  −      25 − −    45     28 − 
Poria sclerotium  − − − − − − − 
Amomum seed      15     40      45 − − − − 
Zedoary rhizome − − − − − − − 
Sophora root −     53 − −    47 − − 
Coptis rhizome −     47 −      9    30    14 − 
           The possible assignable PA species are 16:0/18:3 (34:3), 16:0/18:2 (34:2), 16:0/18:1 (34:1), 
18:2/18:3 (36:5), 18:1/18:3 or 18:2/18:2 (36:4), 18:1/18:2 (36:3), and 18:1/18:1 (36: 2). *Total 
carbon number and number of double bonds in the fatty acid residues. The horizontal dashes lines 
indicate "not detectable". Our detection limit of PA in MALDI-TOF MS method is around 3 
nmol/g herbs.  
           Supplementary Table 3. Molecular species composition of LPA in medicinal herbs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fatty acyl moieties of LPA are designated in terms of the number of 
carbon atoms and double bonds. The horizontal dashes lines indicate "not 
detectable". Our detection limit of LPA in MALDI-TOF MS method is 
around 3 nmol/g herb.  
 16:0 18:1  18:2  18:3  
Peony root     29 −     71 − 
Cimicifuga rhizome    42       8     41      9 
Platycodon root    12 −     83      4 
Panax rhizome    42 −     58 − 
Atractylodes rhizome    33 −     67 − 
Atractylodes lancea rhizome    41 −     58 − 
Phellodendron bark     36 −     56     8 
Ginger rhizome (steamed)    23      41     36 − 
Corydalis tuber    35 −     59     6 
Licorice root     17      14     58    11 
Ginger rhizome (dry)     44 −     46 − 
Moutan cortex     21      14     57      8 
Fennel fruit    41      27     32 − 
Pinellia tuber     41 −     58 − 
Bupleurum root     100 − − − 
Schisandra fruit  − − − − 
Poria sclerotium − − − − 
Amomum seed  − − − − 
Zedoary rhizome − − − − 
Sophora root − − − − 
Coptis rhizome − − − − 
Highlights 
 
• The concentration of LPA in mouse stomach fluid was determined to be 2.4 μM. 
• Peony root powder, a medicinal herb used for the treatment of gastrointestinal disorders, 
contained highly concentrated LPA.   
• The lipid of peony root showed an ameliorative effect against indomethacin-induced 
gastric ulcer in mice. 
• LPA and LPA-rich herbal lipid enhanced PGE2 production and reduce cytotoxicity of 
NSAIDs in gastric cells. 
 
 
